BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24115092)

  • 1. Preclinical safety and activity of recombinant VSV-IFN-β in an immunocompetent model of squamous cell carcinoma of the head and neck.
    Kurisetty VV; Heiber J; Myers R; Pereira GS; Goodwin JW; Federspiel MJ; Russell SJ; Peng KW; Barber G; Merchan JR
    Head Neck; 2014 Nov; 36(11):1619-27. PubMed ID: 24115092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined VSV oncolytic virus and chemotherapy for squamous cell carcinoma.
    Sung CK; Choi B; Wanna G; Genden EM; Woo SL; Shin EJ
    Laryngoscope; 2008 Feb; 118(2):237-42. PubMed ID: 18043494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer.
    Liu YP; Steele MB; Suksanpaisan L; Federspiel MJ; Russell SJ; Peng KW; Bakkum-Gamez JN
    Gynecol Oncol; 2014 Jan; 132(1):194-202. PubMed ID: 24246772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
    Saloura V; Wang LC; Fridlender ZG; Sun J; Cheng G; Kapoor V; Sterman DH; Harty RN; Okumura A; Barber GN; Vile RG; Federspiel MJ; Russell SJ; Litzky L; Albelda SM
    Hum Gene Ther; 2010 Jan; 21(1):51-64. PubMed ID: 19715403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
    Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
    Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors.
    Escobar-Zarate D; Liu YP; Suksanpaisan L; Russell SJ; Peng KW
    Cancer Gene Ther; 2013 Oct; 20(10):582-9. PubMed ID: 24030211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
    Willmon CL; Saloura V; Fridlender ZG; Wongthida P; Diaz RM; Thompson J; Kottke T; Federspiel M; Barber G; Albelda SM; Vile RG
    Cancer Res; 2009 Oct; 69(19):7713-20. PubMed ID: 19773437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats.
    Shinozaki K; Ebert O; Suriawinata A; Thung SN; Woo SL
    J Virol; 2005 Nov; 79(21):13705-13. PubMed ID: 16227290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
    Wollmann G; Paglino JC; Maloney PR; Ahmadi SA; van den Pol AN
    Virology; 2015 Jan; 475():1-14. PubMed ID: 25462341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of cervical carcinoma cells to vesicular stomatitis virus-induced oncolysis: potential role of human papilloma virus infection.
    Le Boeuf F; Niknejad N; Wang J; Auer R; Weberpals JI; Bell JC; Dimitroulakos J
    Int J Cancer; 2012 Aug; 131(3):E204-15. PubMed ID: 22173567
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular determinants of susceptibility to oncolytic vesicular stomatitis virus in pancreatic adenocarcinoma.
    Blackham AU; Northrup SA; Willingham M; Sirintrapun J; Russell GB; Lyles DS; Stewart JH
    J Surg Res; 2014 Apr; 187(2):412-26. PubMed ID: 24252853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.
    Obuchi M; Fernandez M; Barber GN
    J Virol; 2003 Aug; 77(16):8843-56. PubMed ID: 12885903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variation in susceptibility of human malignant melanomas to oncolytic vesicular stomatitis virus.
    Blackham AU; Northrup SA; Willingham M; D'Agostino RB; Lyles DS; Stewart JH
    Surgery; 2013 Mar; 153(3):333-43. PubMed ID: 23102637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production.
    Alain T; Lun X; Martineau Y; Sean P; Pulendran B; Petroulakis E; Zemp FJ; Lemay CG; Roy D; Bell JC; Thomas G; Kozma SC; Forsyth PA; Costa-Mattioli M; Sonenberg N
    Proc Natl Acad Sci U S A; 2010 Jan; 107(4):1576-81. PubMed ID: 20080710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS.
    Zhang L; Steele MB; Jenks N; Grell J; Suksanpaisan L; Naik S; Federspiel MJ; Lacy MQ; Russell SJ; Peng KW
    Hum Gene Ther Clin Dev; 2016 Sep; 27(3):111-22. PubMed ID: 27532609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety studies on intrahepatic or intratumoral injection of oncolytic vesicular stomatitis virus expressing interferon-beta in rodents and nonhuman primates.
    Jenks N; Myers R; Greiner SM; Thompson J; Mader EK; Greenslade A; Griesmann GE; Federspiel MJ; Rakela J; Borad MJ; Vile RG; Barber GN; Meier TR; Blanco MC; Carlson SK; Russell SJ; Peng KW
    Hum Gene Ther; 2010 Apr; 21(4):451-62. PubMed ID: 19911974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus core protein enhances hepatocellular carcinoma cells to be susceptible to oncolytic vesicular stomatitis virus through down-regulation of HDAC4.
    Moon J; Kaowinn S; Cho IR; Min DS; Myung H; Oh S; Kaewpiboon C; Kraemer OH; Chung YH
    Biochem Biophys Res Commun; 2016 Jun; 474(3):428-434. PubMed ID: 27150631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation Attenuates Prostate Tumor Antiviral Responses to Vesicular Stomatitis Virus Containing IFNβ, Resulting in Pronounced Antitumor Systemic Immune Responses.
    Udayakumar TS; Betancourt DM; Ahmad A; Tao W; Totiger TM; Patel M; Marples B; Barber G; Pollack A
    Mol Cancer Res; 2020 Aug; 18(8):1232-1243. PubMed ID: 32366674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.